Profile image
By Alton Parrish (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Reschedule Marijuana to a Schedule II Substance Urges Medical Society

Thursday, October 13, 2016 11:46
% of readers think this story is Fact. Add your two cents.
Clinical evidence supports the use of marijuana for intractable chronic pain. However, there is a lack of evidence regarding the long-term effects of marijuana use, and overlapping state and federal laws create huge obstacles for physicians who may want to prescribe it. This puts pain physicians in a challenging position.

It also makes them key players in this ongoing debate.

“Many patients could potentially benefit from its use,” said The American Society of Regional Anesthesia and Pain Medicine (ASRA) Board member Samer Narouze, MD, PhD. “Neuropathic pain is probably the indication with the most convincing clinical evidence,” he said. Other indications with promising results include anxiety, depression, seizures, cancer pain, and HIV-related pain.

“However, because medical marijuana lacks the FDA quality and safety oversight, there is inconsistency in doses, which can pose potential risk to patients,” Narouze said.

  Credit: Pixabay

In response to these challenges, ASRA has issued a formal position statement calling for rescheduling of marijuana and more clinical outcomes research to determine its safety and effectiveness as a medical intervention.

Marijuana is classified as a Schedule 1 substance with “no currently accepted medical use and a high potential for abuse,” according to federal law. As a result, it cannot be readily studied in clinical trials. There is a dearth of information regarding the long-term effects of marijuana use, specifically its effects on learning and cognitive function. “Cannabis use disorder” is a recognized disorder in patients who continue to use cannabis despite clinically significant impairment.

According to Dr. Narouze, evidence has shown that, in addition to clinical evidence supporting its use, medical marijuana is associated with significant decreases in drug prescriptions, particularly opioid prescriptions, as well as reduced costs in those states in which medical marijuana laws were implemented.1

By downgrading marijuana to a Schedule II substance, the federal government would enable researchers to study it in clinical trials, leading to a better understanding of who would benefit from its use, as well as assisting in development of formulations with minimal side effects.

The ASRA Board of Directors approved the “ASRA Statement on Cannabis” at its September 30th Board meeting. In it, ASRA “pleads” to the National Institutes of Health to implement guidelines to encourage clinical research of various cannabis preparations, to better understand the long-term safety profile, and to compare marijuana to other analgesics.



Contacts and sources:
The American Society of Regional Anesthesia and Pain Medicine
Read the entire position here.

1. Bradford AC, et al. Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D.Health Aff (Millwood). 2016 Jul 1;35(7):1230-6. doi: 10.1377/hlthaff.2015.1661.


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.